---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-013073"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:20:46.474473+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MaxCyte Q2 revenue $9.6M (+35% YoY); raises 2022 core revenue growth guidance to ~30%

## Summary
- Total revenue $9.6M (+35% YoY); core business revenue +45% led by cell therapy +61%.
- Net loss $8.3M (vs $4.4M loss Q2 2021); operating expenses $17.2M (up from $10.7M).
- Cash & investments $240.9M as of June 30, 2022.
- Raised 2022 core revenue growth guidance to ~30%; SPL program-related revenue expected ~$4M.
- Signed 17th SPL agreement in July 2022 with LG Chem.

## SEC filing metadata
- accession: 0001558370-22-013073
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837022013073/0001558370-22-013073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837022013073/mxct-20220810x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-013073
- JSON: https://secwatch.observer/filing/0001558370-22-013073.json
- Plain text: https://secwatch.observer/filing/0001558370-22-013073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.